BCI Pharma will take the benefit of the expertise of their founders to initiate research projects in virology.
The main goals will be:
a) To deliver pre-IND candidates for unmet needs in viral diseases
(Dengue, Human papilloma virus and other viral diseases with a niche market)
b) To discover new ones based on new technology to reduce the administered dose (pill burden), thus reducing side effects (less toxicity), extending the timing between doses and increasing compliance.
We want to improve the quality of life of the patient.